GLP-1 analogues, which are currently approved for T2DM treatment, have been repeatedly shown to exert neurotrophic/restorative effects in a range of animal models of AD, PD, ALS, TBI and experimental stroke11–18,40–48. This evidence concerns the gene GLP1R and Parkinson disease.